ocriplasmin
Sign in to saveAlso known as microplasmin
Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.
In the Vinony graph
Vinony's link graph records 6 inbound references to ocriplasmin, and connects out to European Union, Wayback Machine and digital object identifier.
It is catalogued under topics including Chemicals that do not have a ChemSpider ID assigned, Drug has EMA link and Drugs with non-standard legal status.
Vinony links it to 10 Wikipedia language editions.
Key facts
- Drug.tradename
- Jetrea
- Drug.licence_EU
- yes
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravitreal
- Drug.ATC_prefix
- S01
- Drug.ATC_suffix
- XA22
- Drug.legal_AU
- S4
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1048016-09-6
- Drug.IUPHAR_ligand
- 7446
- Drug.DrugBank
- DB08888
- Drug.UNII
- 7V6HE3DM5A
- Drug.ChemSpiderID
- none
- Drug.KEGG
- D09646
- Drug.C
- 1214
- Drug.H
- 1890
- Drug.N
- 338
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2010
- Admin. routes
- parenteral
- Indications
- stroke, deep vein thrombosis, retinal vein occlusion, uveitis
via ChEMBL · EBI
Wikidata facts
- Subclass of
- peptidase
- Has use
- medication
Show 1 more fact
- has characteristic
- biopharmaceutical
via Wikidata · CC0
~2 min read
Encyclopedic overview
5 sectionsContents
- Structure
- Mechanism of action
- FDA regulation
- Sales
- References
Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.
== Structure == Ocriplasmin is an injectable drug that is "a truncated form of the human serine protease plasmin." The protease plasmin still retains its enzymatic properties. Ocriplasmin consists of two polypeptide chains that are linked by disulfide bonds. Additionally, the longer peptide chain has four disulfide bonds. Ocriplasmin is only moderately stable when injected, and this is due to autolytic degradation.
Excerpted from Wikipedia’s “ocriplasmin” article, available under the CC BY-SA 4.0 licence.
Available in 10 languages
via Wikidata sitelinks · CC0